Cancer is one of the leading causes of death in the United States along with heart disease.
The hallmark of cancer treatment has been conventional chemotherapy. Chemotherapeutic …

Immunotoxins are proteins that contain a toxin along with an antibody or growth factor that
binds specifically to target cells. Nearly all protein toxins work by enzymatically inhibiting …

Retinoids have numerous applications in inflammatory, dyskeratotic, and oncohematology
diseases. Retinoids have now reached the fourth generation, progressively reducing toxicity …

The management goal in cutaneous T‐cell lymphomas (CTCLs) is to improve symptoms and
induce remission. Early‐stage disease is generally treated with skin‐directed therapies …

Depsipeptide (FK228) is a novel histone deacetylase inhibitor currently in clinical trials and
the first to demonstrate clinical activity in patients. Responses have been observed in …

Bexarotene (Targretin®, Ligand Pharmaceuticals Inc.) is a synthetic retinoid analog with
specific affinity for the retinoid X receptor and belongs to a group of compounds called …

Background Cutaneous T-cell lymphoma (CTCL) represents a spectrum of diseases
composed of malignant T lymphocytes. The most common type is mycosis fungoides (MF) …

Through years of evolutionary selection pressures, organisms have developed potent toxins
that coincidentally have marked antineoplastic activity. These natural products have been …

Retinoids are biologic regulators of differentiation, proliferation, apoptosis, and immune
response. Retinoids (all‐trans retinoic acid, 13‐cis‐retinoic acid, and the synthetic analogs …

Disease overview: Cutaneous T‐cell lymphomas are a heterogenous group of T‐cell
lymphoproliferative disorders involving the skin, the majority of which may be classified as …